The developments of silicosis drugs
10.16438/j.0513-4870.2022-1412
- VernacularTitle:矽肺药物治疗的研究进展
- Author:
Tong-tong LIU
;
Yan-xing HAN
;
Jian-dong JIANG
;
Yun ZHAN
- Publication Type:Research Article
- Keywords:
silicosis;
fibrosis;
inflammation;
anti-oxidation;
cytokine;
medication
- From:
Acta Pharmaceutica Sinica
2023;58(5):1196-1203
- CountryChina
- Language:Chinese
-
Abstract:
Pneumoconiosis is the most common occupational disease in China, which severely endangers people's health. Depending on the inhaled air pollutants, pneumoconiosis is classified as anthracosis, silicosis, asbestosis, etc., among which silicosis is the most common and serious. Silicosis is a systemic, poor prognostic disease characterized by diffuse fibrosis of lung tissue, which is caused by long-term exposure to dust with high levels of free silicon dioxide (SiO2) in the occupational environment. Appropriate treatment in time is important for the disease. Unfortunately, no effective drugs have been approved to delay or even reverse pulmonary fibrosis caused by SiO2. This review briefly classifies potent therapeutic drugs and compounds in term of mechanisms, providing the probability for clinical treatment of silicosis.
